Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › nemolizumab

nemolizumab

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of nemolizumab

12 trials tracked of nemolizumab: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 207 citations.

12Trials tracked
5Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 5 Phase 2 6 Phase 1 1
  1. Phase 3 A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Completed · 207 cited
  2. Phase 3 Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Completed · 171 cited
  3. Phase 3 Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Completed · 158 cited
  4. Phase 3 A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis Completed
  5. Phase 3 To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus Completed
  6. Phase 2 A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis Completed
Show 6 more trials
  1. Phase 2 Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis Completed
  2. Phase 2 A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab Completed
  3. Phase 2 An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis Completed
  4. Phase 2 A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD) Completed
  5. Phase 2 Dose-ranging Study of Nemolizumab in Atopic Dermatitis Completed
  6. Phase 1 Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
EMA-approved biologics and JAK inhibitors show meaningful short-term EASI-75 responses in moderate-to-severe atopic dermatitis
Allergy & Immunology Meta-analysis
EMA-approved biologics and JAK inhibitors show meaningful short-term EASI-75 responses in moderate-to-severe atopic dermatitis Newer Eczema Drugs Clear Skin for Many, But Comparisons Are Tricky
This systematic review narratively synthesized randomized trials of EMA-approved systemic therapies for moderate-to-severe atopic dermatitis…
Seven eczema drugs helped 18% to 73% of adults reach clearer skin in 12 to 16 weeks. But trials varied too much to say which works best.
Frontiers Oct 31, 2026
Nemolizumab Q4W improves IGA success maintenance by 11.8% over withdrawal in atopic dermatitis
Dermatology RCT
Nemolizumab Q4W improves IGA success maintenance by 11.8% over withdrawal in atopic dermatitis Trial shows nemolizumab maintains skin results for atopic dermatitis
This Phase 3 randomized controlled trial evaluated nemolizumab in 507 adolescents and adults with moderate-to-severe atopic dermatitis who w…
A new trial found that nemolizumab helps maintain clear skin and reduce itching for adults and teens with moderate to severe atopic dermatit…
Jun 13, 2026
Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy
Neurology Meta-analysis
Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy Dupilumab and Pimecrolimus Lead New Rankings for Children's Eczema Relief
This network meta-analysis evaluated dupilumab, pimecrolimus, melatonin, probiotics, tralokinumab, nemolizumab, and vitamin D for pediatric …
A new analysis ranks the top treatments for children's eczema, with dupilumab and pimecrolimus leading for symptom relief.
Frontiers May 2, 2026